For laboratory and educational research use only. Not medical advice.
Women's Peptide Research
Ask Vera
Home  /  Database  /  Tesofensine
Weight & Metabolicphase_2_3

Tesofensine

NS2330
Weight & Metabolic
ASK VERA ABOUT THIS ↗BROWSE THE CATALOG ↗
Category
Weight & Metabolic
Evidence grade
B
PubMed records
56
Female-tagged
12
Sex-analysis
1
CAS
—
B
Evidence grade B, Phase 2/3 human trial evidence across 56 indexed studies (mixed-sex). How grades work →
Female evidence: Extrapolated
Tesofensine: of 56 PubMed records, 12 are tagged as including female subjects and 1 carry a sex-analysis tag.Counts reflect PubMed records as of 2026-07-21. “Female” uses the Female MeSH filter and “sex-analysis” the Sex Factors MeSH filter, automated proxies pending manual study-level review. Methodology →

Overview

Tesofensine is a small-molecule triple monoamine-reuptake inhibitor, meaning it acts on the reuptake of noradrenaline, dopamine, and serotonin at the synaptic level. Originally advanced in central-nervous-system research programs, its combined activity across these three transmitter systems gives it a distinctive pharmacological profile that has drawn interest in appetite and energy-balance research.

In preclinical and clinical research models, tesofensine has been studied for its relationship to satiety signaling, food-intake regulation, and central pathways governing energy expenditure. Investigators examining monoaminergic contributions to appetite have used it as a research material to probe how simultaneous modulation of these transmitters relates to feeding behavior and metabolic set points.

What makes tesofensine a useful entry for a weight and metabolic catalog is the breadth of its studied mechanism across three neurotransmitter systems at once. Whether these mechanisms translate uniformly to female physiology remains an open research question; our evidence review tracks how many of the underlying studies included women.

Summary

Tesofensine is a serotonin-noradrenaline-dopamine reuptake inhibitor that produced notable weight loss in Phase 2 obesity trials after failing as a Parkinson's/Alzheimer's therapy. It remains investigational in most markets; trials enrolled women but were not analyzed by sex.

Evidence in women

Menstrual cycle
Unstudied
No study examined weight or mood response across the menstrual cycle.
Pregnancy & lactation
Unstudied
No pregnancy or lactation safety data; centrally-acting appetite suppressants are generally avoided in pregnancy.
Hormonal interactions
Unstudied
No controlled data on interactions with contraceptives or thyroid hormones.
Perimenopause & menopause
Unstudied
No perimenopause- or menopause-specific analyses.
Sex differences
Unstudied
Obesity trials enrolled women, but published results were not analyzed by sex.

Mechanism

Inhibits presynaptic reuptake of noradrenaline, dopamine, and serotonin, reducing appetite and increasing satiety.

Reported dosing & routes

◐

We don't give dosing or medical advice. The figures below describe what was used in published research, not a recommendation. Decide with your clinician.

Reported range (literature)0.25–1 mg/day oral studied in Phase 2 obesity trials; investigational.
Routesoral
Female-specific dosingNot established

Contraindications: cardiovascular disease or uncontrolled hypertension (stimulant-like effects)

Side effects

Reported in the research literature. Sex-specific incidence has not been separately analysed in the available records.

increased heart rate and blood pressuredry mouthinsomnianausea

Tesofensine reconstitution calculator

Enter this vial's amount, the bacteriostatic water you add, and a target amount to get the concentration and the U-100 syringe units to draw. Handling arithmetic for research use, not a dose recommendation.

Reconstitution

1
2
3

Draw for Tesofensine

5
units on a U-100 insulin syringe
020406080100
U-100 insulin syringe — 1 mL = 100 units
That's 0.05 mL drawn to the 5-unit mark.
Concentration5 mg/mL (5,000 mcg/mL)
Volume to draw0.05 mL
Doses per vial40

Reference chart at 5 mg/mL

Target amountVolume (mL)U-100 units
100 mcg0.02 mL2
250 mcg0.05 mL5
500 mcg0.1 mL10
750 mcg0.15 mL15
1000 mcg0.2 mL20

Research-use arithmetic only. This tool converts a vial amount, diluent volume, and a target amount into a concentration and syringe draw for laboratory handling. It is not dosing guidance, a recommendation, or a claim of safety or efficacy, and it does not account for overfill, dead space, or peptide purity. Nothing here is medical advice. “U-100” means 100 units = 1 mL; confirm your syringe graduation before measuring. See the reconstitution & storage handbook for handling detail.

Frequently asked questions

Answers drawn only from Tesofensine's research facts and, where reviewed, its sex-disaggregated evidence. Nothing here is medical advice, dosing, or a claim of safety or efficacy.

What is Tesofensine?

Tesofensine, also known as NS2330, is a research compound in our weight metabolic category. Tesofensine is a serotonin-noradrenaline-dopamine reuptake inhibitor that produced notable weight loss in Phase 2 obesity trials after failing as a Parkinson's/Alzheimer's therapy.

Is Tesofensine studied in women?

Tesofensine: of 56 PubMed records, 12 are tagged as including female subjects and 1 carry a sex-analysis tag. We grade this extrapolated: women appear in the record, but no study is tagged for a sex-specific analysis, so female-relevant conclusions are inferred from mixed or male data rather than measured in women. See our methodology.

Has Tesofensine been studied during pregnancy or breastfeeding?

Unstudied. No pregnancy or lactation safety data; centrally-acting appetite suppressants are generally avoided in pregnancy. This is not a safety clearance or a recommendation. Vera, our research chat, deliberately hard-stops on pregnancy, breastfeeding, and trying-to-conceive questions rather than answer them.

What evidence grade does Tesofensine have, and why?

Tesofensine carries evidence grade B. Phase 2/3 human trial evidence across 56 indexed studies (mixed-sex).. Grades are derived from the research record, never hand-assigned; see how grades work.

Is there a female-specific dose for Tesofensine?

No. A female-specific dose for Tesofensine is not established, and this site does not provide dosing or medical advice. Any figures we show describe what published research used, not a recommendation. Decide anything about use with a qualified clinician.

How is Tesofensine administered in research?

In the published literature, Tesofensine is administered via oral. Reported dose ranges on the Dosing tab describe what studies used for laboratory research, not a protocol for people. We don't provide dosing.

What side effects have been reported for Tesofensine?

Effects reported in the research literature include increased heart rate and blood pressure, dry mouth, insomnia, nausea. Sex-specific incidence has not been separately analysed in the available records, so these are not broken out for women.

How should Tesofensine be stored and handled?

Tesofensine sold for research is supplied as a lyophilized (freeze-dried) powder. Lyophilized peptides are generally kept cold and dry, at roughly -20°C for longer-term storage and 2-8°C short-term, protected from light. Once reconstituted they are typically refrigerated and used within a short window, avoiding repeated freeze-thaw cycles. This is general laboratory handling for research use only, not a directive for human use. Always follow the handling and purity details on the product's Certificate of Analysis.

Where can I buy Tesofensine for research?

Tesofensine is not currently listed by our research-use partner, Aurevena Research, but their catalog carries related compounds. Code research15 applies 15% off. We may earn a commission when you purchase through this link, at no extra cost to you. Products are for laboratory research use only.

Browse the Aurevena catalog
Research-use supplier: Tesofensine isn't currently listed by our research-use vendor. Their catalog carries related compounds. Code research15 for 15% off, applied automatically at checkout. We may earn a commission when you purchase through this link, at no extra cost to you. Products are for laboratory research use only.
Browse the catalog →

Citations (PMID)

19777399 · 24064009

Related peptides

4X Blend (Methionine / Choline / Carnitine / Dexpanthenol)·
Multi-ingredient blend, its female evidence is reviewed per ingredient, not for the combination.
5-Amino-1MQD
5-Amino-1MQ: of 3 PubMed records, 2 are tagged as including female subjects and 0 carry a sex-analysis tag.
8X Blend (L-Carnitine / L-Arginine / Methionine / Inositol / Choline / B6 / B5 / B12)·
Multi-ingredient blend, its female evidence is reviewed per ingredient, not for the combination.
AdipotideD
Adipotide: of 4 PubMed records, 2 are tagged as including female subjects and 0 carry a sex-analysis tag.

Educational information for laboratory and research use only. Not medical advice, a recommendation, or a claim of safety or efficacy; no personal dosing. “Unstudied” means no qualifying study was found, not that a compound is safe or unsafe.